| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
*
Division of Rheumatology and Clinical Immunology, Department of Medicine,
University of Pittsburgh Arthritis Institute, and
Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261
The cellular and subcellular events governing Ab production with specificity for self Ags are poorly understood. In this study we examined the role of cellular interactions and cytokines in regulating the production of anti-DNA topoisomerase I (topo I) Ab, a major autoantibody in patients with systemic sclerosis (SSc). Topo I-specific T cell clones derived from SSc subjects and healthy donors were cultured with autologous peripheral blood B cells. Anti-topo I Ab production was induced by five of seven topo I-specific T cell clones derived from SSc subjects, but by none of eight T cell clones generated from healthy controls. However, two of the T cell clones from healthy controls provided help to HLA-DR-matched SSc B cells to produce anti-topo I Ab. The analysis of cytokine mRNA expression revealed that the ability to promote anti-topo I autoantibody production was strictly correlated with IL-2 and IL-6 expression by the T cell clones. Kinetic studies showed that IL-2 was required throughout the culture period for maximal autoantibody production and that both MHC-TCR and CD40-CD40L interactions were essential during the early phase of the culture. IL-6 was important in the late phase. Th1 clones (producing IL-2, but no IL-6) and Th2 clones (producing IL-6, but no IL-2) synergically activated autologous B cells to produce anti-topo I Ab. These results indicate that T cell-dependent B cell activation resulting in anti-topo I autoantibody production requires a series of temporally defined cell contact and soluble stimuli.
This article has been cited by other articles:
|
|
 |
|
  H. Takahashi, M. Amagai, T. Nishikawa, Y. Fujii, Y. Kawakami, and M. Kuwana Novel System Evaluating In Vivo Pathogenicity of Desmoglein 3-Reactive T Cell Clones Using Murine Pemphigus Vulgaris J. Immunol., July 15, 2008; 181(2): 1526 - 1535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Tulunay, S Yavuz, H Direskeneli, and E Eksioglu-Demiralp CD8+CD28-, suppressive T cells in systemic lupus erythematosus Lupus, July 1, 2008; 17(7): 630 - 637. [Abstract] [PDF]
|
|
|
|
|
|
H. Yasuoka, H. Ihn, T. A. Medsger Jr, M. Hirakata, Y. Kawakami, Y. Ikeda, and M. Kuwana A Novel Protein Highly Expressed in Testis Is Overexpressed in Systemic Sclerosis Fibroblasts and Targeted by Autoantibodies J. Immunol., December 15, 2003; 171(12): 6883 - 6890. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kuwana, Y. Kawakami, and Y. Ikeda Suppression of autoreactive T-cell response to glycoprotein IIb/IIIa by blockade of CD40/CD154 interaction: implications for treatment of immune thrombocytopenic purpura Blood, January 15, 2003; 101(2): 621 - 623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Veldman, A. Stauber, R. Wassmuth, W. Uter, G. Schuler, and M. Hertl Dichotomy of Autoreactive Th1 and Th2 Cell Responses to Desmoglein 3 in Patients with Pemphigus Vulgaris (PV) and Healthy Carriers of PV-Associated HLA Class II Alleles J. Immunol., January 1, 2003; 170(1): 635 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Ascherman, T. B. Oriss, C. V. Oddis, and T. M. Wright Critical Requirement for Professional APCs in Eliciting T Cell Responses to Novel Fragments of Histidyl-tRNA Synthetase (Jo-1) in Jo-1 Antibody-Positive Polymyositis J. Immunol., December 15, 2002; 169(12): 7127 - 7134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kodama, T. Hirotani, Y. Suzuki, S. Ogawa, and K. Yamazaki Cardiomyogenic Differentiation in Cardiac Myxoma Expressing Lineage-Specific Transcription Factors Am. J. Pathol., August 1, 2002; 161(2): 381 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Arai, K. Yoshida, J. Kaburaki, H. Inoko, Y. Ikeda, Y. Kawakami, and M. Kuwana Autoreactive CD4+ T-cell clones to {beta}2-glycoprotein I in patients with antiphospholipid syndrome: preferential recognition of the major phospholipid-binding site Blood, September 15, 2001; 98(6): 1889 - 1896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kuwana, J. Kaburaki, H. Kitasato, M. Kato, S. Kawai, Y. Kawakami, and Y. Ikeda Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura Blood, July 1, 2001; 98(1): 130 - 139. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
